Reply to “On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs"

Abstract We previously concluded that 12 common excipients need not be qualitatively the same and quantitatively very similar to reference for Biopharmaceutics Classification System–based biowaivers. This conclusion for regulatory relief is based upon a series of bioequivalence studies in humans involving cimetidine and acyclovir. Limitations were also discussed. We understand the major concern of García-Arieta et al. is that “results obtained by Vaithianathan et al. should not be extrapolated to other drugs.” We understand that individuals conducting their own risk/benefit analysis may reach that conclusion, and we reply to the concerns of García-Arieta et al. We continue to conclude that the 12 common excipients need not be qualitatively the same nor quantitatively very similar to reference, but rather, simply be not more than the quantities studied in our manuscript for cimetidine and acyclovir, and potentially other class 3 drugs with similar properties.

Keywords biopharmaceutics classification system; bioequivalence; excipient; oral absorption; permeability; cimetidine; acyclovir

Download
Reply to “On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs”
Soundarya Vaithianathan1, Sam H. Haidar2, Xinyuan Zhang2, Wenlei Jiang2, Christopher Avon1, Thomas C. Dowling3, Changxing Shao1, Maureen Kane1, Stephen W. Hoag1, Mark H. Flasar4, Tricia Y. Ting5, James E. Polli1, ,
doi:10.1016/j.xphs.2016.02.028
1-s2.0-S0022354916003944-main.pdf
Adobe Acrobat Document 169.7 KB